For decades, a disease carried silently by more than seven million people has gone largely untreated — not for lack of medicine, but because the medicine itself was too difficult to bear. A seven-year clinical trial called TESEO has now demonstrated that a shorter, gentler course of benznidazole works just as well against Trypanosoma cruzi as the punishing regimen designed half a century ago, offering a path toward treating one of the world's most neglected diseases with far greater compassion and reach.
Shorter benznidazole course cuts Chagas treatment side effects by 40%
Over 7 million people worldwide are infected with Trypanosoma cruzi, with 30-40% developing serious Chagas disease complications, yet fewer than 1% are diagnosed and treated.